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OBJECTIVES: Vitamin K is thought to be involved in both
bone health and maintenance of neuromuscular function.
We tested the effect of vitamin K2 supplementation on pos-
tural sway, falls, healthcare costs, and indices of physical
function in older people at risk of falls.
DESIGN: Parallel-group double-blind randomized placebo-
controlled trial.
SETTING: Fourteen primary care practices in Scotland, UK.
PARTICIPANTS: A total of 95 community-dwelling partic-
ipants aged 65 and older with at least two falls, or one inju-
rious fall, in the previous year.
INTERVENTION: Once/day placebo, 200 μg or 400 μg of
oral vitamin K2 for 1 year.
MEASUREMENTS: The primary outcome was antero-
posterior sway measured using sway plates at 12 months,
adjusted for baseline. Secondary outcomes included the
Short Physical Performance Battery, Berg Balance Scale,
Timed Up & Go Test, quality of life, health and social care
costs, falls, and adverse events.
RESULTS: Mean participant age was 75 (standard deviation
[SD] = 7) years. Overall, 58 of 95 (61%) were female; 77 of
95 (81%) attended the 12-month visit. No signiﬁcant effect of
either vitamin K2 dose was seen on the primary outcome of
anteroposterior sway (200 μg vs placebo: −.19 cm [95% conﬁ-
dence interval [CI] −.68 to .30; P = .44]; 400 μg vs placebo:
.17 cm [95% CI −.33 to .66; P = .50]; or 400 μg vs 200 μg:
.36 cm [95% CI −.11 to .83; P = .14]). Adjusted falls rates were
similar in each group. No signiﬁcant treatment effects were seen
for other measures of sway or secondary outcomes. Costs were
higher in both vitamin K2 arms than in the placebo arm.
CONCLUSION: Oral vitamin K2 supplementation did not
improve postural sway or physical function in older people
at risk of falls. J Am Geriatr Soc 67:2102-2107, 2019.
Key words: falls; vitamin K; postural sway; health eco-
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Current evidence suggests that multifactorial falls interven-tions (combining strength and balance training, home
environment modiﬁcation, calcium and vitamin D supplemen-
tation, cataract extraction, and medication review) reduce falls
in selected patients,1 but the magnitude of effect is modest.
Furthermore, such interventions are expensive,2 labor inten-
sive, and appear less successful when applied to a general older
population3,4 than when applied to more highly selected
groups of at-risk individuals referred to falls clinics. New sim-
ple and inexpensive ways of reducing falls in the wider popula-
tion of older people are therefore needed.
Vitamin K is an essential cofactor for gamma carboxyla-
tion, required for the effective function of a range of proteins5
including those involved in bone remodeling, vascular calciﬁca-
tion, glucose handling, inﬂammation, and neuromuscular func-
tion.6-12 Low levels of dietary vitamin K intake are very
common and associated with a higher risk of cardiovascular
disease and osteoporosis.13,14
In our previouswork, a nonsigniﬁcant improvement in pos-
tural swaywas seenwith 6months of once/day supplementation
From the *AGE Research Group, NIHR Newcastle Biomedical Research
Centre, Newcastle University and Newcastle upon Tyne Hospitals Trust,
Newcastle upon Tyne, United Kingdom; †School of Medicine, University of
Dundee, Dundee, United Kingdom; ‡Tayside Clinical Trials Unit, University
of Dundee, Dundee, United Kingdom; §School of Nursing, Abertay
University, Dundee, United Kingdom; ¶Health Economics Research Unit,
University of Aberdeen, Aberdeen, United Kingdom; ∥Centre for Clinical
Brain Sciences, University of Edinburgh, Edinburgh, UK and NHS Fife,
Kirkcaldy, United Kingdom; and the **Ageing Clinical and Experimental
Research, School of Medicine & Dentistry, University of Aberdeen,
Aberdeen, United Kingdom.
Address correspondence to Miles Witham, AGE Research Group, NIHR
Newcastle Biomedical Research Centre, Biomedical Research Building,
Campus for Ageing and Vitality, Newcastle NE4 5PL, United Kingdom;
E-mail: miles.witham@newcastle.ac.uk; Twitter: @OlderTrialsProf
This work was presented at the British Geriatrics Society Spring scientiﬁc
meeting, held in Cardiff, UK, April 10, 2019. Trial Registration:
ISRCTN18436190.
DOI: 10.1111/jgs.16024
JAGS 67:2102-2107, 2019
© 2019 The Authors
Journal of the American Geriatrics Society published by Wiley Periodicals, Inc. on behalf of The American Geriatrics Society. 0002-8614/19/$15.00
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which
permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not
used for commercial purposes.
with 100 μg vitamin K2 in participants aged 70 and older with
vascular disease.15 Before conducting a large trial to evaluate
whether vitamin K supplementation can reduce falls in older
people at high risk, it is necessary to test which dose of vitamin
K is effective (using a surrogate marker of falls risk) and to test
whether recruitment to such a trial is feasible. The aims of this
trial were therefore ﬁrst to establish the optimum vitamin K
dose to improve postural sway in older people, second to test
recruitment strategy and likely effect size, and third to conduct
preliminary health economic analyses to inform the design of
future large multicenter trials of vitamin K to reduce falls in at-
risk older people.
METHODS
Trial Design
This was a randomized double-blind parallel-group placebo-
controlled trial. Ethics approval was obtained from East of
Scotland Research Ethics committee (approval number
15/ES/0197), and the trial was registered at http://isrctn.com
(ISRCTN18436190). Written informed consent was obtained
from all participants at the screening visit.
Population and Recruitment
We recruited community-dwelling participants aged
65 and older with either two or more falls in the previous
12 months, or at least one fall resulting in hospitalization
in the last 12 months. Exclusion criteria were an inability
to give written informed consent; unable to stand without
human assistance; atrial ﬁbrillation (because this group
should usually be taking warfarin); taking warfarin or
other coumadin derivatives; taking more than 100 μg vita-
min K supplement per day; known contraindication to
vitamin K; currently enrolled in, or within 30 days of com-
pleting another trial; currently undertaking physiotherapy
or another time-limited supervised nonpharmacologic
intervention to reduce falls risk; and intolerance to soy
products. All participants were recruited via primary care
from three Health Board areas (Tayside, Grampian, and
Fife). Telephone prescreening was conducted, and those
eligible at this stage were invited to a combined screening
and baseline visit.
Intervention and Comparator
Matching tablets containing either 200 μg vitamin K2
(MK7 subtype), 400 μg vitamin K2 (MK7 subtype), or
placebo were manufactured and bottled by Legosan AB
(Kumla, Sweden) and distributed to sites by Tayside Phar-
maceuticals (Dundee, Scotland). The trial product was
provided in identical bottles with a unique trial identiﬁer
on each bottle to ensure masking to participants, clini-
cians, and researchers. Participants were asked to take
one tablet each day for the 12 months of the trial. No
clear evidence exists to favor vitamin K1 or K2, or to
favor a particular subtype of vitamin K2. However, MK7
was the subtype used in our previous trial that suggested
possible beneﬁt on postural sway.15 Thus this subtype was
selected for use in the current trial but at higher doses than
we used previously.
Randomization and Allocation Concealment
Randomization was performed in a 1:1:1 ratio by an
online-based randomization system, run by the Health
Informatics Centre, University of Dundee, to ensue alloca-
tion concealment. A minimization algorithm with a small
random element was used to ensure balance across recruit-
ment centers and key baseline measures. Minimization fac-
tors were trial center (Tayside, Grampian, or Fife), age (>80
or ≤80 y), and baseline anteroposterior (AP) sway (>3 cm
or ≤3 cm).
Outcomes
The primary outcome was the between-group difference in AP
sway at 12 months, measured using the AMTI AccuSway
sway platform (AMTI, Watertown, MA, USA). Sway was
measured with participants standing with feet together on the
platform; three 30-second runs were performed with eyes
open, followed by three 30-second runs with eyes closed.
Sampling rate was 100 Hz, and proprietary software (AMTI
Balance Clinic) was used to derive the outcome measures
from raw center of pressure data. The mean value of each set
of three runs was taken as the outcome measure. AP sway
was previously shown to predict future falls in a range of
populations.16-18 The secondary outcomes were other markers
of postural sway (mediolateral sway, 95% ellipse, total path
length) compared between groups at 6 and 12 months; Berg
Balance Scale,19 the Short Physical Performance Battery,20
Timed Up & Go Test,21 falls frequency collected using
monthly falls diaries,22 and desphospho-undercarboxylated
matrix Gla protein (dp-ucMGP) levels as a measure of the bio-
logical effect of vitamin K.23 The dp-ucMGP was measured
using a semi-commercial enzyme-linked immunosorbent assay
by VitaK (Maastricht, Netherlands).24 Ofﬁce blood pressure
was measured using an OMRON HEM-705 oscillometric
device (OMRON). Participants were rested in a supine posi-
tion for a minimum of 5 minutes, supine blood pressure was
measured three times, and the mean of the second and third
readings was used. Postural drop in blood pressure was mea-
sured as the largest drop between supine blood pressure and
standing blood pressure measured immediately on standing,
at 1 minute, and 3 minutes. We also collected health and
social care utilization at each visit, and quality of life using
the EuroQoL EQ5D-5 L and the Investigating Choice Exper-
iments for the preferences of older people Capability Tool
for Older People (ICECAP-O) tools.25,26 Adherence was
measured by tablet count, comparing the number returned
with the number expected to be returned at each study visit.
All assessments were conducted by research nurses masked
to treatment allocation.
Analysis
All analyses were conducted according to a prespeciﬁed
statistical analysis plan, using SPSS software v.22 (IBM,
Armonk, NY, USA). A two-sided P value <.015 was
taken as signiﬁcant for all analyses. Details of the analy-
sis and sample size calculations are provided in Supple-
mentary Material S1.
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RESULTS
We sent study information to 4145 individuals identiﬁed from
screening 14 primary care practices (6 in Tayside, 4 in
Grampian, and 4 in Fife). A total of 444 expressed interest in
the trial, of whom 99 attended a screening visit and 95 were
randomized between June 28, 2016, and July 4, 2017.
Baseline details of those randomized are given in Table 1;
Supplementary Material S1 shows the Consolidated Stan-
dards of Reporting Trials diagram for participant ﬂow
through the trial. No signiﬁcant difference in adherence
was found between groups: 90% (SD = 20) in the 200 μg
vitamin K group, 82% (SD = 27) in the 400 μg vitamin K
group, and 88% (SD = 33) in the placebo group (P > .05
for all comparisons).
Figure 1 and Table 2 show the primary outcome results. No
signiﬁcant differences in AP sway were seen between groups at
12 months, either adjusted for baseline or adjusted for minimi-
zation variables. Table 2 and Supplementary Material S1 show
the secondary outcomes. No signiﬁcant differences were seen
between groups for other measures of sway, for blood pressure,
or formeasures of physical performance. Dp-ucMGP levels were
signiﬁcantly lower, however, in the 200 μg and 400 μg vitamin
K2 groups than in the placebo group, conﬁrming that vitamin
K was producing the expected dose-dependent effect on this
marker of vitamin K biological activity. Supplementary Mate-
rial S1 contains the results of falls analyses. The treatment
groups did not show a statistically signiﬁcantly different falls
rate to placebo, although falls rates were higher in the 200-μg
arm. Time to ﬁrst fall was also not signiﬁcantly different from
placebo in the treatment groups. There were more adverse
events in the 200-μg arm than in the placebo or 400-μg arms as
shown in Supplementary Material S1. This was driven by a
slightly higher rate of gastrointestinal adverse events and a
higher injury rate, paralleling the higher falls rate seen in the
200-μg arm.
Table 1. Baseline Characteristics
Placebo
(n = 32)
Vitamin K
200 μg (n = 32)
Vitamin K
400 μg (n = 31)
Mean age, y (SD) 75.0 (6.9) 74.7 (7.4) 75.1 (6.5)
Female sex (%) 18 (56) 21 (66) 19 (61)
Median number of falls in last year (IQR) 3 (2-7) 3 (2-6) 3 (2-4)
Uses walking aid (%) 21 (66) 15 (47) 12 (39)
Previous myocardial infarction (%) 2 (6) 1 (3) 1 (3)
Chronic heart failure (%) 0 (0) 1 (3) 0 (0)
Parkinsonian syndrome (%) 0 (0) 0 (0) 0 (0)
Previous stroke (%) 2 (6) 2 (6) 3 (10)
Hypertension (%) 17 (53) 15 (47) 18 (58)
Diabetes mellitus (%) 6 (19) 1 (3)* 8 (26)
Peripheral neuropathy (%) 4 (13) 1 (3) 2 (6)
Previous fragility fracture (%) 8 (25) 14 (44) 12 (39)
Osteoarthritis (%) 15 (47) 19 (59) 18 (58)
Chronic obstructive pulmonary disease (%) 4 (13) 7 (22) 6 (19)
Cataracts (%) 9 (28) 15 (47) 12 (39)
Retinopathy (%) 2 (6) 1 (3) 3 (10)
Median no. of medications (IQR) 5 (4-8) 6 (3-10) 6 (4-9)
ACEi/ARB (%) 14 (44) 12 (38) 12 (39)
Other antihypertensive or antianginal (%) 13 (41) 14 (44) 15 (48)
Vitamin D or analog (%) 4 (13) 12 (38)* 12 (39)*
Bisphosphonate (%) 1 (3) 5 (16) 5 (16)
Antidepressant (%) 8 (25) 8 (25) 7 (23)
Hypnotic (%) 5 (16) 0 (0)* 1 (3)
Opioid (%) 13 (41) 10 (31) 8 (26)
Mean body mass index, kg/m2 (SD) 29.7 (4.7) 29.4 (5.1) 30.8 (7.9)
Anteroposterior sway, cm (SD) 2.74 (1.01) 2.95 (.88) 2.93 (1.21)
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; IQR, interquartile range; SD, standard deviation.
*P < .05 compared with placebo.
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Figure 1. Anteroposterior sway at each time point by treatment
group. CI, conﬁdence interval.
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Costs were lowest over 1 year among participants
randomized to the placebo group (mean cost = £764 per
participant). Costs were lower among participants in the
low-dose vitamin K2 group, relative to high-dose vitamin
K2 (£896-£902 vs £1033-£1044). Supplementary Material
S1 combines the data just cited to show the incremental
costs and quality-adjusted life years for the 200 μg and
400 μg vitamin K2 arms compared with placebo. Neither
dose of vitamin K2 produced any improvement relative to
placebo. Supplementary Material S1 shows the Expected
Value of Sample Information graph. Based on the assump-
tions used, the optimal sample size for the most cost-
effective future trial would be 131 participants per group,
but such a trial would remain cost effective up to a sample
size of 1100 per group.
DISCUSSION
There are a number of possible explanations for the lack of
observed beneﬁt of vitamin K supplementation that merit
consideration. Adherence was good, and the Dp-ucMGP
results conﬁrm that the vitamin K had a measurable biolog-
ical effect, but it is still possible that an even larger dose is
required to improve sway or that vitamin K has to be given
for longer to achieve an effect. The study population was at
risk of falls, as shown by the average of 1.7 falls per partici-
pant during the trial. However, postural sway was relatively
low in the trial population. Thus a ceiling effect may have
limited the ability of the trial interventions to produce a
measurable change. A more challenging balance task than
standing on a ﬁrm level surface may be required to allow
Table 2. Anteroposterior Sway and Physical Performance Measures
Baseline 6 mo 12 mo
Unadjusted anteroposterior sway, cm (SD) Placebo 2.74 (1.01) 2.84 (1.35) 2.75 (1.38)
Vitamin K 200 μg 2.95 (.88) 3.01 (1.33) 2.51 (1.02)
Vitamin K 400 μg 2.93 (1.21) 2.67 (1.22) 2.88 (1.20)
Treatment effect at 12 mo, cm (95% CI) p
Adjusted for baseline 200 μg vs placebo −.19 (−.68 to .30) .44
400 μg vs placebo .17 (−.33 to .66) .50
200 μg vs 400 μg .36 (−.11 to .83) .14
Fully adjusteda 200 μg vs placebo −.09 (−.53 to .35) .69
400 μg vs placebo .19 (−.25 to .63) .40
200 μg vs 400 μg .28 (−.15 to .70) .20
Multiple imputationa 200 μg vs placebo −.20 (−.66 to .26) .39
400 μg vs placebo .04 (−.44 to .51) .88
200 μg vs 400 μg .24 (−.22 to .67) .31
Repeated measuresa 200 μg vs placebo −.07 (−.43 to .30) .72
400 μg vs placebo −.08 (−.44 to .28) .66
200 μg vs 400 μg −.02 (−.37 to .34) .93
Baseline 6 mo 12 mo
Unadjusted SPPB (mean, SD) Placebo 7.7 (2.3) 8.0 (2.7) 7.9 (3.0)
Vitamin K 200 μg 7.4 (2.6) 7.8 (2.7) 7.8 (2.7)
Vitamin K 400 μg 7.1 (2.7) 7.2 (2.8) 6.7 (3.1)
Treatment effect at 12 mo P
SPPB treatment effecta (95% CI) 200 μg vs placebo −.2 (−1.1 to .7) .63
400 μg vs placebo −.4 (−1.3 to .5) .37
200 μg vs 400 μg −.2 (−1.1 to .7) .66
Baseline 6 mo 12 mo
Unadjusted Timed Up & Go (median, IQR) Placebo 12.9 [9.7-17.1] 9.9 [8.5-16.2] 11.2 [9.1-17.2]
Vitamin K 200 μg 14.2 [9.2-21.3] 11.7 [8.4-18.1] 12.5 [8.9-19.0]
Vitamin K 400 μg 14.1 [9.4-20.4] 12.9 [8.4-17.9] 13.3 [9.6-18.7]
Treatment effect at 12 mo P
Log10 Timed Up & Go Test treatment effecta (95% CI) 200 μg vs placebo .02 (−.03 to .07) .44
400 μg vs placebo .03 (−.02 to .09) .23
200 μg vs 400 μg .01 (−.04 to .06) .64
Baseline 6 mo 12 mo
Unadjusted Berg Balance Scale (median, IQR) Placebo 50 [45-53] 51 [38-53] 52 [41-54]
Vitamin K 200 μg 48 [42-53] 52 [46-54] 50 [47-54]
Vitamin K 400 μg 48 [44-54] 47 [42-54] 49 [40-54]
Treatment effect at 12 mo P
Log10 Berg Balance Scale treatment effecta (95% CI) 200 μg vs placebo .00 (−.00 to .02) .31
400 μg vs placebo −.00 (−.02 to .01) .80
200 μg vs 400 μg −.01 (−.03 to .00) .20
Abbreviation: CI, conﬁdence interval; IQR, interquartile range; SD, standard deviation; SPPB, Short Physical Performance Battery.
aAdjusted for age, sex, baseline anteroposterior sway, and trial center.
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any beneﬁt of the intervention to be observed in this partici-
pant group. Although previous studies found that many
older people have low dietary vitamin K intakes, we did not
examine dietary intake of vitamin K via food diaries in this
trial, and so we cannot be sure if the trial population had
particularly low vitamin K intakes. However, the fact that
both 200-μg and 400-μg doses of vitamin K signiﬁcantly
lowered dp-ucMGP levels suggests that participants were
not vitamin K replete at baseline.
One previous trial examined the effect of vitamin K
supplementation on postural sway; this trial did not ﬁnd a
signiﬁcant beneﬁt of lower dose vitamin K supplementation
on this outcome.15 Previous trials suggest, but do not estab-
lish conclusively, a beneﬁcial effect on vascular health of
vitamin K. A recent meta-analysis7 showed statistically sig-
niﬁcant improvements in vascular calciﬁcation but not in
vascular stiffness, arguably a more important functional
measure of vascular health and one that has been linked to
orthostatic hypotension, a potential mediator of falls. It is
possible that an even longer duration of therapy is required
to produce beneﬁt from vitamin K supplementation; one
trial in postmenopausal women did not ﬁnd signiﬁcant ben-
eﬁt before the third year of supplementation.27
Our trial has a number of strengths. The groups were
balanced at baseline, the trial recruited participants at an
elevated risk of falls, and both retention and intervention
adherence were good. The involvement of multiple recruit-
ment and assessment center improves the generalizability of
our results. A number of additional limitations require com-
ment. Effects in people with different ethnicity or diet cannot
be ascertained because the trial population were overwhelm-
ingly white, and dietary information was not collected. The
trial was not powered to detect a difference in falls rates, and
thus an effect on falls rates cannot be excluded; such an
effect could be mediated by mechanisms other than improve-
ments in postural sway or orthostatic hypotension that we
did not measure in this trial.
It is possible that populations at higher risk (eg, those
in nursing homes, falls clinics, or those with very low vita-
min K intake) could still potentially beneﬁt, and future
research could usefully target these groups. At present,
however, insufﬁcient evidence exists to recommend use of
vitamin K supplementation in community-dwelling older
adults at risk of falls.
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